Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
4.095
+0.115 (2.89%)
Oct 16, 2025, 12:56 PM EDT - Market open
Agenus Revenue
Agenus had revenue of $25.69M in the quarter ending June 30, 2025, with 9.28% growth. This brings the company's revenue in the last twelve months to $101.71M, down -36.29% year-over-year. In the year 2024, Agenus had annual revenue of $103.46M, down -33.81%.
Revenue (ttm)
$101.71M
Revenue Growth
-36.29%
P/S Ratio
0.95
Revenue / Employee
$321,854
Employees
316
Market Cap
130.48M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 103.46M | -52.85M | -33.81% |
| Dec 31, 2023 | 156.31M | 58.29M | 59.47% |
| Dec 31, 2022 | 98.02M | -197.64M | -66.85% |
| Dec 31, 2021 | 295.67M | 207.50M | 235.34% |
| Dec 31, 2020 | 88.17M | -61.88M | -41.24% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
AGEN News
- 5 weeks ago - France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer - Business Wire
- 5 weeks ago - Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - Business Wire
- 6 weeks ago - Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript) - Seeking Alpha
- 7 weeks ago - Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight - Business Wire
- 2 months ago - Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025 - Business Wire
- 2 months ago - Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress - Business Wire
- 2 months ago - Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report - Business Wire
- 2 months ago - Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025 - Business Wire